Erik Koenig

1.7k total citations
19 papers, 893 citations indexed

About

Erik Koenig is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Erik Koenig has authored 19 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 8 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Erik Koenig's work include Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (6 papers) and Peptidase Inhibition and Analysis (3 papers). Erik Koenig is often cited by papers focused on Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (6 papers) and Peptidase Inhibition and Analysis (3 papers). Erik Koenig collaborates with scholars based in United States, Netherlands and Japan. Erik Koenig's co-authors include Paul G. Richardson, Yongsheng Huang, John D. Shaughnessy, George Mulligan, Dixie‐Lee Esseltine, Steven Roels, Allison Berger, Anthony Boral, Fenghuang Zhan and P. Leif Bergsagel and has published in prestigious journals such as The EMBO Journal, Blood and PLoS ONE.

In The Last Decade

Erik Koenig

18 papers receiving 872 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Koenig United States 8 676 218 212 208 185 19 893
Joseph P. Milazzo United States 10 973 1.4× 140 0.6× 414 2.0× 173 0.8× 153 0.8× 10 1.3k
Tai‐Chung Huang Taiwan 16 376 0.6× 172 0.8× 154 0.7× 47 0.2× 173 0.9× 39 761
Celia Sigua United States 9 738 1.1× 266 1.2× 143 0.7× 65 0.3× 84 0.5× 15 948
Yin Tong China 15 325 0.5× 145 0.7× 203 1.0× 78 0.4× 56 0.3× 45 603
Aaron Nguyen United States 12 695 1.0× 421 1.9× 207 1.0× 46 0.2× 65 0.4× 21 966
Julia Etchin United States 11 1.2k 1.7× 232 1.1× 297 1.4× 29 0.1× 184 1.0× 18 1.4k
Van S. Tompkins United States 18 724 1.1× 129 0.6× 481 2.3× 95 0.5× 160 0.9× 35 1.1k
Winnie F. Tam United States 12 491 0.7× 131 0.6× 183 0.9× 59 0.3× 309 1.7× 20 866
Marjan Yaghmaie Iran 15 384 0.6× 153 0.7× 118 0.6× 37 0.2× 210 1.1× 64 705
Charlie Hatton United States 12 976 1.4× 323 1.5× 348 1.6× 34 0.2× 93 0.5× 21 1.2k

Countries citing papers authored by Erik Koenig

Since Specialization
Citations

This map shows the geographic impact of Erik Koenig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Koenig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Koenig more than expected).

Fields of papers citing papers by Erik Koenig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Koenig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Koenig. The network helps show where Erik Koenig may publish in the future.

Co-authorship network of co-authors of Erik Koenig

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Koenig. A scholar is included among the top collaborators of Erik Koenig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Koenig. Erik Koenig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Berger, Allison, Sharon Friedlander, Omid Ghasemi, et al.. (2019). Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model. Cancer Research. 79(13_Supplement). 3079–3079. 4 indexed citations
2.
Berger, Allison, Sharon Friedlander, Omid Ghasemi, et al.. (2019). Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model. 3079–3079. 1 indexed citations
3.
Amidon, Benjamin, Dongyun Wu, John Bradley, et al.. (2017). Abstract 1493: LonP1 is required for tumor maintenance and growth. Cancer Research. 77(13_Supplement). 1493–1493. 1 indexed citations
4.
5.
Koenig, Erik, Craig D. Fisher, Hugues Bernard, et al.. (2016). The beagle dog MicroRNA tissue atlas: identifying translatable biomarkers of organ toxicity. BMC Genomics. 17(1). 649–649. 49 indexed citations
6.
Wolenski, Francis S., Pooja Shah, Tomoya Sano, et al.. (2016). Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. Journal of Applied Toxicology. 37(3). 278–286. 33 indexed citations
7.
Chattopadhyay, Nibedita, Allison Berger, Erik Koenig, et al.. (2015). KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. PLoS ONE. 10(12). e0144825–e0144825. 14 indexed citations
8.
Mandelbaum, Jonathan, Pooja Shah, Doug Bowman, et al.. (2015). Identification of a lung cancer cell line deficient in atg7-dependent autophagy. Autophagy. 0–0. 35 indexed citations
9.
Bouck, David C., Khristofer Garcia, Jonathan L. Blank, et al.. (2015). Abstract C55: Nedd8-activating enzyme inhibitor pevonedistat synergizes with cisplatin and carboplatin through interference with nucleotide excision repair and interstrand cross-link repair mechanisms in non-small cell lung cancer. Molecular Cancer Therapeutics. 14(12_Supplement_2). C55–C55. 1 indexed citations
10.
Milhollen, Michael A., Marc L. Hyer, Jeff Ciavarri, et al.. (2014). 561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study. European Journal of Cancer. 50. 181–182. 1 indexed citations
11.
Koenig, Erik, Pooja Shah, Michael Fitzgerald, et al.. (2013). Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models.. Molecular Cancer Therapeutics. 12(11_Supplement). A169–A169. 2 indexed citations
12.
Koenig, Erik, George Mulligan, Eric S. Lightcap, et al.. (2011). Abstract A196: Development, validation, and clinical implementation of a peripheral blood RT-PCR pharmacodynamic assay for MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE).. Molecular Cancer Therapeutics. 10(11_Supplement). A196–A196. 1 indexed citations
13.
14.
Milhollen, Michael A., Tary Traore, Michael P. Thomas, et al.. (2010). MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma. Blood. 116(9). 1515–1523. 270 indexed citations
15.
Donelan, Jill, Bret Bannerman, Paul Hales, et al.. (2009). Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma.. Blood. 114(22). 3724–3724. 1 indexed citations
16.
Traore, Tary, James Garnsey, Erik Koenig, et al.. (2009). Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.. Blood. 114(22). 927–927. 2 indexed citations
17.
Mulligan, George, Steven Roels, Andrew Bolt, et al.. (2007). Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma.. Blood. 110(11). 392–392. 1 indexed citations
18.
Mulligan, George, Constantine S. Mitsiades, Barbara M. Bryant, et al.. (2006). Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 109(8). 3177–3188. 302 indexed citations
19.
Pays, Étienne, Hélène Coquelet, Patricia Tebabi, et al.. (1990). Trypanosoma brucei: constitutive activity of the VSG and procyclin gene promoters.. The EMBO Journal. 9(10). 3145–3151. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph P. Milazzo Breakdown of academic impact, for papers by Tai‐Chung Huang Breakdown of academic impact, for papers by Celia Sigua Breakdown of academic impact, for papers by Yin Tong Breakdown of academic impact, for papers by Aaron Nguyen Breakdown of academic impact, for papers by Julia Etchin Breakdown of academic impact, for papers by Van S. Tompkins Breakdown of academic impact, for papers by Winnie F. Tam Breakdown of academic impact, for papers by Marjan Yaghmaie Breakdown of academic impact, for papers by Charlie Hatton
Rankless by CCL
2026